Loading stock data…
ASND
$213.23+7.42 (+3.61%)
After Hours$213.23+0.00 (+0.00%)· Last close Jun 9
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ascendis Pharma A/S in the Healthcare sector is trading at $213.23 with a market capitalization of $13.8B. Wall Street consensus targets $295.70 (17 analysts), implying a +38.7% move over the next 12 months. The stock is currently 15% below its 52-week high of $250.74, remaining 1.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +38.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$213.23
Potential Upside
19.5%
Whystock Fair Value$254.82
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Mean target$295.70+38.7%
Range$251.12 – $352.17
Fundamentals
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.85B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.44
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
101.63%
Volume
Today's trading volume
461,601
Recent News
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness
Event context and recent price moves Ascendis Pharma (NasdaqGS:ASND) has recently drawn investor attention after the stock fell about 4% in a day and is down roughly 4% over the past week and 12% over the past month. See our latest analysis for Ascendis Pharma. At a share price of $210.45, Ascendis Pharma’s recent pullback, including a 1-month share price return of down 11.82% and year to date share price return of down 14.24%, points to fading near term momentum despite earlier gains. If you...
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
European equities traded in the US as American depositary receipts were rising late Friday morning,
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were trending higher late Tuesday
Spyglass Capital Dumps $26 Million of Global-e Online Amid Stock's 24% Decline
Global-E Online enables cross-border e-commerce for retailers and brands, serving international merchants through its proprietary platform.